BioNexus Gene Lab Corp Common stock (BGLC)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ
Market Cap: $2.41M
Last updated: Nov 17, 2026 at 4:10 PM ET
BioNexus Gene Lab Corp Common stock (BGLC) Statistics
BioNexus Gene Lab Corp Common stock (BGLC) has a market cap of $2.41M and an enterprise value of $1.17M. Its share count is up 63.28% from a year earlier. It kept -84.93% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 51.25% below the market cap, as cash exceeds debt.
| Market Cap | $2.41M |
|---|---|
| Enterprise Value | $1.17M |
| Latest price (Nov 17, 2026) | $0.77 |
Key Dates
| Last Earnings Date | Aug 14, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 83.09% over 52 weeks and trades 35.83% below its 50-day average.
| Beta (1Y) | 1.55 |
|---|---|
| 52-Week Change | -83.09% |
| 1-Month Change | -37.60% |
| 3-Month Change | -51.20% |
| 6-Month Change | -63.51% |
| 5-Year Change | -99.60% |
| Total Return (1Y) | -83.09% |
| Total Return (3Y CAGR) | -38.53% |
| Total Return (5Y CAGR) | -68.12% |
| Max Drawdown (1Y) | -84.07% |
| Max Drawdown (3Y) | -95.12% |
| Sharpe Ratio (1Y) | -2.57 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $1.20 |
| 200-Day Average | $1.83 |
| 52-Week Range | $0.80 to $4.97 |
| RSI (14 Days) | 30.8 |
| Average Volume (20 Days) | 6.33K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.08x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.08x |
|---|---|
| Quick Ratio | 5.28x |
| Debt / Equity | 0.00x |
| Interest Coverage | -136.85x |
Returns and Efficiency
Return on equity is -34.14% over the last 12 months, against a 5-year average of -15.19%.
| Return on Equity (ROE) | -34.14% |
|---|---|
| Return on Assets (ROA) | -30.43% |
| Return on Capital Employed (ROCE) | -31.45% |
| ROE (5Y Average) | -15.19% |
| ROA (5Y Average) | -13.37% |
| ROIC (5Y Average) | -25.78% |
| Asset Turnover | 0.34x |
| Inventory Turnover | 4.00x |
| Receivables Turnover | 21.32x |
| Cash Conversion Cycle | 25 days |
Scores
BGLC has an Altman Z-Score of 0.24, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.24 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.13M over the last 12 months is down 67.27% from the 12 months before.
| Revenue | $3.13M |
|---|---|
| Revenue Growth (YoY) | -67.27% |
| Gross Profit | $385.89K |
| Operating Income | -$2.56M |
| Pretax Income | -$2.58M |
| Net Income | -$2.66M |
| EBITDA | -$2.31M |
| EBIT | -$2.49M |
| Reported EPS (TTM) | -$1.27 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 89.12% of the $8.73M in total assets.
| Cash and Equivalents | $1.23M |
|---|---|
| Total Debt | $0 |
| Net Cash | $1.23M |
| Net Cash Per Share | $0.42 |
| Working Capital | $4.13M |
| Shareholder Equity | $7.78M |
| Total Assets | $8.73M |
| Total Liabilities | $947.98K |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $7.04K of capital spending, operating cash flow left -$853.60K of free cash flow.
| Operating Cash Flow | -$846.57K |
|---|---|
| Capital Expenditures | $7.04K |
| Free Cash Flow | -$853.60K |
| FCF Per Share | -$0.29 |
| Depreciation and Amortization | $176.83K |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -81.82%, against a 5-year average of -15.56%.
| Gross Margin | 12.34% |
|---|---|
| Operating Margin | -81.82% |
| Pretax Margin | -82.36% |
| Net Margin | -84.93% |
| EBITDA Margin | -73.94% |
| EBIT Margin | -79.60% |
| FCF Margin | -27.30% |
| Gross Margin (5Y Average) | 14.05% |
| Operating Margin (5Y Average) | -15.56% |
| Net Margin (5Y Average) | -16.31% |
Growth
Revenue fell 12.09% a year over 3 years.
| Revenue Growth (3Y CAGR) | -12.09% |
|---|---|
| Revenue Growth (5Y CAGR) | -8.20% |
Dividends and Yields
BGLC does not pay a dividend. Its free cash flow yield is -37.98%.
| FCF Yield | -37.98% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Apr 7, 2025.
| Last Split Date | Apr 7, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BGLC
What is BGLC's market cap?
BioNexus Gene Lab Corp Common stock has a market cap of $2.41M. Its enterprise value, which adds debt and subtracts cash, is $1.17M.
How many shares of BGLC are outstanding?
BioNexus Gene Lab Corp Common stock has 2.93M shares outstanding. The count is up 63.28% from a year earlier.
Does BGLC pay a dividend?
No. BioNexus Gene Lab Corp Common stock does not pay a dividend.
How much debt does BGLC have?
BioNexus Gene Lab Corp Common stock has $0 of total debt and $1.23M of cash and equivalents, a net cash position of $1.23M.
BGLC pages: Overview, Charting, Financials, Statistics